Short Interest in Cellectis S.A. (NASDAQ:CLLS) Drops By 55.0%

Cellectis S.A. (NASDAQ:CLLS) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 156,200 shares, a drop of 55.0% from the October 15th total of 346,800 shares. Based on an average trading volume of 43,600 shares, the short-interest ratio is currently 3.6 days.

Cellectis Trading Up 0.3 %

Shares of Cellectis stock traded up $0.01 during trading hours on Wednesday, reaching $1.98. The stock had a trading volume of 33,012 shares, compared to its average volume of 50,185. Cellectis has a 1 year low of $1.70 and a 1 year high of $3.77. The firm has a market capitalization of $110.06 million, a price-to-earnings ratio of -1.50 and a beta of 3.10. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $2.25.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the previous year, the company earned ($0.31) earnings per share. As a group, equities research analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CLLS shares. Barclays decreased their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. StockNews.com started coverage on Cellectis in a research note on Wednesday. They issued a “sell” rating for the company.

Institutional Investors Weigh In On Cellectis

Several hedge funds and other institutional investors have recently bought and sold shares of CLLS. XTX Topco Ltd bought a new stake in shares of Cellectis during the 2nd quarter worth $29,000. First Affirmative Financial Network acquired a new position in shares of Cellectis in the third quarter worth about $45,000. Principal Financial Group Inc. raised its holdings in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC grew its position in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.